Skip to content
LTX-315 / Studies
Synthetic analog · 9 amino acids · 1,439.8 Da

LTX-315 studies and research data

PepBank has 38 LTX-315 studies with results. 25 of them gave LTX-315, with 142 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 142 results and 61 papers. Newer studies from Europe PMC

Results in people
18
13% of 142 results
Results in animals
50
35% of 142 results
Results in lab cells
74
52% of 142 results
From computer models
0
0% of 142 results
The molecule

LTX-315 identity

Identifiers, parent molecule, targets and development stage, from curated data.

LTX-315, also called ruxotemitide, is a nine-residue oncolytic peptide. It contains a non-proteinogenic diphenylalanine residue and a C-terminal amide. Its tumor studies do not establish an approved cancer treatment.

Kind
Synthetic analog · 9 residues
Identifiers
ChEMBLCHEMBL4297628 (opens in a new tab)PubChem CID46200994 (opens in a new tab)UNII75FBL12IZ7 (opens in a new tab)DrugBankDB12748 (opens in a new tab)CAS1345407-05-7
Development
Phase 2Lytix BiopharmaSeven distinct human interventional registrations test LTX-315 or its VP-315 name. Five completed records report positive actual enrollment. NCT01986426 has estimated registry enrollment but a publication reports 39 treated patients. NCT06651151 is recruiting with estimated enrollment, which does not establish treatment. None of these seven records is withdrawn with zero enrollment. Highest confirmed registered phase is phase 2. Lytix develops LTX-315, with Verrica developing VP-315 for dermatologic oncology. Planned phase 3 programs do not establish a completed phase 3 trial. Source (opens in a new tab)

Targets

No molecular target is recorded for this peptide.

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

9 amino acids · 2 modifications

H-
Residues 1 to 9:
KKWWKKWK
  • AromaticF W Y
  • PositiveK R H
  • Non-canonicalX
  • Modified residue

Modifications

9
C-terminal amide
C-terminal carboxamide.
8
Non-canonical residue
X denotes (S)-3,3-diphenylalanine (Dip), also called beta-phenyl-L-phenylalanine.

Properties

From identity sources

Formula
C78H106N18O9
Molecular weight
1,439.8 g/mol
Monoisotopic mass
1,438.839 Da

Calculated from the sequence

Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Average mass
Not calculated
Monoisotopic mass
Not calculated
Isoelectric point (pI)
Not calculated
Net charge at pH 7.4
Not calculated
GRAVY (hydropathy)
Not calculated
Extinction coefficient, 280 nm (Cys reduced)
16,500 M⁻¹ cm⁻¹
5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index
Not calculated
Aliphatic index
Not calculated
Boman index
Not calculated
Hydrophobic moment (μH)
Not calculated
  • 1 non-canonical residue (X) is not included in calculated values.
  • Defined and validated for proteins; use with care for short peptides.
  • Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Composition

  • Aromatic33% (3)
  • Positive56% (5)
  • Non-canonical11% (1)

9 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%
I Ile0 · 0%
L Leu0 · 0%
M Met0 · 0%
V Val0 · 0%
F Phe0 · 0%
W Trp3 · 33%
Y Tyr0 · 0%
H His0 · 0%
K Lys5 · 56%
R Arg0 · 0%
D Asp0 · 0%
E Glu0 · 0%
N Asn0 · 0%
Q Gln0 · 0%
S Ser0 · 0%
T Thr0 · 0%
C Cys0 · 0%
G Gly0 · 0%
P Pro0 · 0%
X Xaa1 · 11%

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 46200994(opens in a new tab)

C1=CC=C(C=C1)C(C2=CC=CC=C2)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N
Results by area

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Trials and papers
Status and safety
Data